![Updated COVID-19 booster targets subvariants responsible for 98% of cases today | Malheur County Health Department Updated COVID-19 booster targets subvariants responsible for 98% of cases today | Malheur County Health Department](https://i0.wp.com/covidblog.oregon.gov/wp-content/uploads/2022/09/Bivalent_2.jpg?resize=526%2C526&ssl=1)
Updated COVID-19 booster targets subvariants responsible for 98% of cases today | Malheur County Health Department
![Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC) Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)](https://publichealthcollaborative.org/wp-content/uploads/2022/10/ENG_Twitter_updated-booster-doses-2.png)
Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)
![Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health](https://publichealth.jhu.edu/sites/default/files/styles/article_feature/public/2023-02/bivalent-vaccine-g1422104879.jpg?h=f7026c63&itok=62rHr_a_)
Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health
![Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation - The Lancet Infectious Diseases Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/f8841dac-dc6a-4040-8138-e6c2a5eff780/gr1a_lrg.jpg)
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation - The Lancet Infectious Diseases
![Monovalent and bivalent COVID boosters provide strong protection against severe outcomes in older adults Monovalent and bivalent COVID boosters provide strong protection against severe outcomes in older adults](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_745095_16814788526283575.jpg)
Monovalent and bivalent COVID boosters provide strong protection against severe outcomes in older adults
![Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial - Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -](https://www.thelancet.com/cms/asset/3b19b20c-8a5a-43c9-80d5-abbcb3039e22/gr1.jpg)
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -
![ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine | Australian Government Department of Health and Aged Care ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/2023-02/atagi-recommendations-on-use-of-the-moderna-bivalent-original-omicron-ba-4-5-covid-19-vaccine.png?itok=vfz4hhmr)
ATAGI recommendations on use of the Moderna bivalent (Original/Omicron BA.4/5) COVID-19 vaccine | Australian Government Department of Health and Aged Care
![Moderna on X: "@GovCanHealth has authorized the use of our Omicron-targeting #bivalent COVID-19 booster #vaccine, mRNA-1273.214, as a booster dose for active immunization against #COVID19 in individuals 18 years of age and Moderna on X: "@GovCanHealth has authorized the use of our Omicron-targeting #bivalent COVID-19 booster #vaccine, mRNA-1273.214, as a booster dose for active immunization against #COVID19 in individuals 18 years of age and](https://pbs.twimg.com/media/FblEeVcXgAEMY4f.jpg:large)
Moderna on X: "@GovCanHealth has authorized the use of our Omicron-targeting #bivalent COVID-19 booster #vaccine, mRNA-1273.214, as a booster dose for active immunization against #COVID19 in individuals 18 years of age and
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)